Injured by Celebrex Side Effects?
Celebrex is the only COX-2 inhibitor still on the market in the United States. The popular painkiller has been used by millions of Americans and Pfizer is expecting over $2 Billion in sales from the drug Celebrex in 2007 alone.
Celebrex is however linked to serious adverse side effects including heart attacks, strokes and Stevens Johnson Syndrome (SJS).
Update: Schmidt & Clark is no longer accepting Celebrex cases.
What is the Problem?
The Food & Drug Administration in 2005 asked their advisory committee to examine the drug Celebrex to determine whether it offered enough benefits to the consumer stay on the market and whether or not they needed to add stronger warnings to the package inserts. The advisory committee indicated that Celebrex elevates the chances of cardiovascular problems.
Dr. Garret Fitzgerald, a researcher at the University of Pennsylvania, has told the US regulatory panel governing the drug Celebrex that all COX-2 inhibitors increase the risk of heart attacks and strokes. Dr. Fitzgerald has indicated that the body will react the same to Celebrex as it does to Vioxx or Bextra, which have both been removed from the market. Furthermore, Dr. Fitzgerald said that Celebrex creates an imbalance in the body's cardiovascular system that may lead to an increased risk of heart attacks and strokes.
Celebrex Side Effects & Lawsuit News (National)
| Court Won't Alter Ruling Blocking Generic Celebrex Until 2014 - CNN Money NEW YORK -(Dow Jones)- The U.S. Court of Appeals for the Federal Circuit won't alter a March decision blocking Teva Pharmaceutical Industries Ltd. (TEVA) from selling a generic version of Pfizer Inc.'s (PFE) blockbuster painkiller Celebrex for six ... Bextra trial delay doesn't sit well with plaintiff - New London Day The woman whose case against Pfizer Inc. over the death of her husband was expected to set the tone for Bextra lawsuits everywhere has not yet received a settlement proposal, her daughter said this week. The Wall Street Journal reported Monday that ... Weitz & Luxenberg Recognizes Asbestos Dangers in Aging School ... - Forbes Weitz & Luxenberg P.C. (weitzlux.com) would like to take a moment during National Teacher Appreciation Week (May 4 - 10) to spotlight the high incidence of asbestos-related mesothelioma among our nation's school teachers in the hope that it will ... Health Beat - Salem News SHOES: The Center for Rehabilitation and Sports Medicine is offering a free lecture on footwear selection on Monday, May 12, from 7 to 8 p.m. at the Beverly YMCA Sterling Center, Essex Street in Beverly. Brendan Malay, MSPT, CSCS and Melissa Chennel ... The FDA scale-up: good for big pharma or not? - Genetic Engineering News Fact: the FDA relies on user fees since the 1990s with the goal of speeding up drug approvals, meaning it is severely underfunded by the federal government and has not been able to fulfill it's mission based on that alone... NOW the FDA wants to fill ... Ibuprofen May Cut Alzheimer's Risk - WebMD May 5, 2008 -- The long-term use of ibuprofen and possibly other nonsteroidal anti-inflammatory pain relievers may help protect against Alzheimer's disease, but it is still not clear if the risks outweigh the potential benefits. Use of ibuprofen pain ... Idea AG receives two milestone payments ($37 million) from partner ... - Phramalive.com MUNICH, Germany ? May 7, 2008. IDEA AG today announced that it has received two milestone payments under the US licensing agreement with Alpharma Ireland Limited for DiractinŽ (ketoprofen in TransfersomeŽ, formerly known as IDEA-033). The total ... Beasley Allen Believes Bextra Recall Was Long Overdue - PRWeb The law firm is an outspoken leader in the call to remove Celebrex, Vioxx and other "Coxibs" from the market. It is terribly unfortunate that it has taken over 4 months for FDA and Pfizer to do the right thing and recall Bextra Montgomery, AL ( PRWEB ... Beasley Allen Says Bextra Recall May be Too Late for Thousands - PRWeb The Montgomery law firm has filed 161 Bextra, Celebrex and Vioxx lawsuits to date. Montgomery, AL ( PRWEB ) April 15, 2005 -- Law firm Beasley Allen, lead counsel for the first Vioxx lawsuit set for May, believes that Pfizer's Bextra , a COX-2 ... Amylin Pharma Commences Phase 2B Dose-Ranging Study Of Pramlintide ... - RTT News 5/5/2008 6:53:24 PM Monday evening, biopharmaceutical company Amylin Pharmaceuticals, Inc. (AMLN) announced the initiation of a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin ... |
